Dianthus Therapeutics Quarterly Balance Sheet
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics financial position
As of Jun 30, 2026, Dianthus Therapeutics reported total assets of $1.21 billion, up 272.1% from a year earlier against total liabilities of $41.2 million. Shareholders' equity stood at $1.17 billion, or 96.6% of assets. The company held $110.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 26.10, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 110.55M | 627.67M | 51.09M | 55.98M | 13.24M | 10.12M | 22.79M | 33.67M | 314.17M | 329.72M | 132.32M | 157.28M |
| Short-Term Investments | 776.26M | 483.59M | 353.21M | 346.63M | 244.15M | 253.11M | 252.45M | 247.45M | 46.54M | 47.31M | 41.39M | 32.59M |
| Receivables | 106.00K | 1.23M | 52.00K | 5.00M | 39.00K | 1.00M | 0 | 1.39M | 840.00K | 435.00K | 294.00K | 232.00K |
| Total Current Assets | 897.54M | 1.12B | 409.44M | 413.82M | 263.61M | 271.00M | 280.90M | 287.49M | 365.69M | 380.93M | 177.45M | 191.45M |
| Property, Plant & Equipment | 418.00K | 274.00K | 296.00K | 185.00K | 207.00K | 191.00K | 194.00K | 189.00K | 189.00K | 195.00K | 185.00K | 195.00K |
| Long-Term Investments | 303.63M | 113.87M | 110.14M | 152.87M | 51.70M | 68.31M | 81.73M | 61.48M | — | — | 0 | — |
| Total Assets | 1.21B | 1.25B | 530.92M | 577.45M | 326.08M | 348.58M | 374.01M | 354.25M | 368.96M | 382.46M | 179.41M | 192.46M |
| Accounts Payable | 6.39M | 5.27M | 9.72M | 6.71M | 5.40M | 8.27M | 4.58M | 7.57M | 3.69M | 2.61M | 2.61M | 1.37M |
| Total Current Liabilities | 34.39M | 38.28M | 30.73M | 23.86M | 20.09M | 16.95M | 18.45M | 15.71M | 10.03M | 8.96M | 9.63M | 13.08M |
| Total Liabilities | 41.25M | 45.57M | 37.52M | 30.99M | 23.00M | 19.97M | 21.53M | 16.35M | 10.74M | 9.78M | 10.54M | 14.08M |
| Shareholders' Equity | 1.17B | 1.20B | 493.40M | 546.45M | 303.08M | 328.61M | 352.48M | 337.90M | 358.22M | 372.69M | 168.87M | 178.38M |
| Retained Earnings | -427.78M | -377.56M | -336.73M | -272.30M | -235.53M | -203.90M | -174.39M | -145.95M | -120.78M | -103.17M | -89.42M | -78.86M |
| Net Cash (Debt) | 886.81M | 1.11B | 404.30M | 402.61M | 257.39M | 263.23M | 275.24M | 281.12M | 360.71M | 377.04M | 173.72M | 189.87M |
| Shares Outstanding | 54.80M | 54.58M | 43.22M | 42.85M | 32.18M | 32.13M | 31.12M | 29.37M | 29.35M | 29.35M | 14.82M | 14.82M |
This table shows 12 quarterly periods of Dianthus Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a balance sheet?